{"id":2516,"date":"2018-01-19T17:32:16","date_gmt":"2018-01-19T12:02:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2516"},"modified":"2025-05-12T14:47:49","modified_gmt":"2025-05-12T09:17:49","slug":"familial-amyloid-polyneuropathy-uncommon-medical-condition","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition","title":{"rendered":"Familial Amyloid Polyneuropathy \u2013 An uncommon medical condition"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Familial Amyloid Polyneuropathy<\/strong> (also known as transthyretin amyloidosis, TTR, and FAP) is a group of endangering multisystem disorders which are transmitted as an autosomal dominant trait. It is caused by the excessive accumulation of amyloid in the organs and tissues. The first identified cause of FAP is the<strong> Val30Met <\/strong>mutation of the<strong> transthyretin<\/strong> (TTR) gene. The symptomatology and clinical course of FAP can be highly variable which includes frequent weight loss and cardiac involvement followed by ocular or renal complications.<\/p>\n<p style=\"text-align: justify;\">The clinical presentation and incidence of TTR-FAP vary widely across the globe affecting an estimated <strong>10,000<\/strong> people worldwide. Research studies have shown that there are clusters of TTR-FAP patients in Portugal, Japan, and Sweden but they are also prevalent in the United States and some parts of Europe. Both men and women are likely to be affected equally by the disease. First signs of the symptoms usually appear in the third or fourth decade of life. This frequency varies with genetics and ethnic background. The estimated life expectancy of a patient with transthyretin amyloidosis is approximately 10 years.<\/p>\n<p style=\"text-align: justify;\">Pfizer\u2019s <strong>Vyndaqel<\/strong> (tafamidis) is the only commercially available therapy, which was first approved in Europe in 2011. The drug has also been granted <strong>fast-track<\/strong> designation by the <strong>USFDA<\/strong> facilitating its US launch. The working mechanism of this drug is to prevent the misfolding and accumulation of mutated <strong>TTR<\/strong>.<\/p>\n<p style=\"text-align: justify;\">On the other hand, the current therapeutic pipeline for familial amyloid polyneuropathy is at an emerging stage comprising of two key players i.e. <strong>Alnylam\u2019s<\/strong> (<strong>Patisiran<\/strong>) and<strong> Ionis\u2019s<\/strong>&nbsp;(<strong>Inotersenhas<\/strong>). Both of the drugs are filed for NDA to prepare for their expected launch in 2018. Both the drugs have been granted \u201c<strong>Accelerated Assessment<\/strong>\u201d by the <strong>European Medicines Agency<\/strong>. Ionis has also received Priority Review for inotersen from USFDA, whereas Alnylam has requested for the same. The pipeline also includes drug candidates from other companies such as <strong>GlaxoSmithKline<\/strong> and <strong>SOM Biotech<\/strong>\/<strong>Corino Therapeutics<\/strong>, which are developing products and are in the mid-stage (Phase II) of development.<\/p>\n<p style=\"text-align: justify;\">Although, there are only a few companies focused on the R&amp;D for this indication, the recent improvement in the pipeline activities can be viewed as a potential stepping stone for companies aiming to develop and launch their therapies in this indication.<\/p>\n<p><strong><em>Ayushi Sinha<\/em><\/strong><\/p>\n<p><strong><em>Associate Analyst <\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Familial Amyloid Polyneuropathy (also known as transthyretin amyloidosis, TTR, and FAP) is a group of endangering multisystem disorders which are transmitted as an autosomal dominant trait. It is caused by the excessive accumulation of amyloid in the organs and tissues. The first identified cause of FAP is the Val30Met mutation of the transthyretin (TTR) gene. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1325,134,1330,204,1318,1319,1321,1324,704,985,1328,1327,381,1326,1156,1267,1329,1323,1320,595,1322],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-2516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-alnylams","tag-business-consultant","tag-corino-therapeutics","tag-delveinsight","tag-drug-information","tag-familial-amyloid-polyneuropathy","tag-fap","tag-fast-track","tag-fda","tag-glaxosmithkline","tag-inotersenhas","tag-ioniss","tag-market-research","tag-patisiran","tag-pharma-consultant","tag-pharmaceutical-consultancy","tag-som-biotech","tag-transthyretin","tag-ttr","tag-usfda","tag-val30met","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Familial Amyloid Polyneuropathy Market | FAP Market | DelveInsight<\/title>\n<meta name=\"description\" content=\"The first identified cause of Familial Amyloid Polyneuropathy is the Val30Met mutation of the transthyretin (TTR) gene.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Familial Amyloid Polyneuropathy Market | FAP Market | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The first identified cause of Familial Amyloid Polyneuropathy is the Val30Met mutation of the transthyretin (TTR) gene.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-19T12:02:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T09:17:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021659\/chromosome-img1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"982\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Familial Amyloid Polyneuropathy Market | FAP Market | DelveInsight","description":"The first identified cause of Familial Amyloid Polyneuropathy is the Val30Met mutation of the transthyretin (TTR) gene.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition","og_locale":"en_US","og_type":"article","og_title":"Familial Amyloid Polyneuropathy Market | FAP Market | DelveInsight","og_description":"The first identified cause of Familial Amyloid Polyneuropathy is the Val30Met mutation of the transthyretin (TTR) gene.","og_url":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-01-19T12:02:16+00:00","article_modified_time":"2025-05-12T09:17:49+00:00","og_image":[{"width":1280,"height":982,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021659\/chromosome-img1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition","url":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition","name":"Familial Amyloid Polyneuropathy Market | FAP Market | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021659\/chromosome-img1.jpg","datePublished":"2018-01-19T12:02:16+00:00","dateModified":"2025-05-12T09:17:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The first identified cause of Familial Amyloid Polyneuropathy is the Val30Met mutation of the transthyretin (TTR) gene.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/familial-amyloid-polyneuropathy-uncommon-medical-condition#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021659\/chromosome-img1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021659\/chromosome-img1.jpg","width":1280,"height":982},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/01\/09021659\/chromosome-img1-300x230.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alnylam\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Corino Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">drug information<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Familial Amyloid Polyneuropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FAP<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">fast-track<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Inotersenhas<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ionis\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Patisiran<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharmaceutical consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SOM Biotech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">transthyretin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TTR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">USFDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Val30Met<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alnylam\u2019s<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">Corino Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">drug information<\/span>","<span class=\"advgb-post-tax-term\">Familial Amyloid Polyneuropathy<\/span>","<span class=\"advgb-post-tax-term\">FAP<\/span>","<span class=\"advgb-post-tax-term\">fast-track<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Inotersenhas<\/span>","<span class=\"advgb-post-tax-term\">Ionis\u2019s<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Patisiran<\/span>","<span class=\"advgb-post-tax-term\">pharma consultant<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical consultancy<\/span>","<span class=\"advgb-post-tax-term\">SOM Biotech<\/span>","<span class=\"advgb-post-tax-term\">transthyretin<\/span>","<span class=\"advgb-post-tax-term\">TTR<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>","<span class=\"advgb-post-tax-term\">Val30Met<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 19, 2018","modified":"Updated on May 12, 2025"},"absolute_dates_time":{"created":"Posted on Jan 19, 2018 5:32 pm","modified":"Updated on May 12, 2025 2:47 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2516"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2516\/revisions"}],"predecessor-version":[{"id":32066,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2516\/revisions\/32066"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2517"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2516"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2516"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}